REPLY
20.12.2023 09:31:34 CET | Business Wire | Press release
Concept Reply, part of the Reply network of companies and specialised in IoT, is working with MULTIVAC, a leading manufacturer of processing and packaging solutions, to develop smart services for automated machine monitoring. This project is part of the Open Industry 4.0 Alliance initiative, in which industry-specific companies have joined forces to develop common standards for the transformation to the Industrial Internet of Things.
As a member of the Open Industry 4.0 Alliance, Concept Reply contributes its expertise to IoT projects and actively supports the setting of standards in the field of Industrial IoT. In this context, Concept Reply is successfully working for international founding member MULTIVAC on the "smart services" project. This cloud IoT project aims to digitally manage machines - both locally and remotely - to make processes more transparent and to increase the efficiency and productivity of systems.
The cloud IoT platform implemented for MULTIVAC acts as a central monitoring and management instance. The data is processed on the platform and made available to users as smart services in freely configurable dashboards. The use of a micro-front-end architecture on the Azure cloud and the application of modern web technologies form the basis for the future use of AI-based assistants, thus laying the foundation for new business models and a sustainable, resource-efficient smart factory. The combination of cloud & edge computing reduces latency from data acquisition to sensor technology and actuator control. The benefits for the user are real-time data processing, protection against cyber-attacks and direct machine-to-machine communication.
Further projects with MULTIVAC are already in the pipeline to expand industry standards through the intelligent digitalisation of production and to actively shape the future of Industry 4.0. Dr Marius Grathwohl, VP Digital Products and Transformation at MULTIVAC and Member of the Board of the Alliance, concluded: "The successful collaboration between Concept Reply and MULTIVAC is based on the commonality of an open mindset and a shared understanding of Industry 4.0. Both companies are members of the Open Industry 4.0 Alliance, and we already have a common understanding of the architecture".
Together with its members, the Open Industry 4.0 Alliance is developing multi-vendor Industry 4.0 solutions and services for automated production systems and warehouses. Use cases include automated onboarding, device provisioning, device management, digital nameplates, digital twins and automated device lifecycle management. The open technical ecosystems enable machines and applications from different vendors to be networked and data to be securely transported along the value chain.
Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
Concept Reply
Concept Reply is an IoT software developer specializing in the research, development and validation of innovative solutions and supports its customers in the automotive, manufacturing, smart infrastructure and other industries in all matters relating to the Internet of Things (IoT) and cloud computing. The goal is to offer end-to-end solutions along the entire value chain: from the definition of an IoT strategy, through testing and quality assurance, to the implementation of a concrete solution. www.concept.reply.com
MULTIVAC Group
Bundled expertise, innovative top technology and strong brands under one roof: The MULTIVAC Group offers complete solutions for the packaging and processing of food, medical and pharmaceutical products as well as industrial goods - and continues to set new standards in the market as a technology leader. For more than 60 years, the name has stood for stability and values, innovation and sustainability, quality and excellent service. Founded in 1961 in the Allgäu region of Germany, the MULTIVAC Group is now a global solutions provider that helps small and medium-sized companies as well as large corporations to organise their production processes efficiently and in a way that conserves resources. www.multivac.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231220017040/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom